

COUNTRY GENERAL INFORMATION (WHO, 2015)

Total population:	40,235,000
Gender F / M (%):	49.8 / 50.2
Population, age group <15/≥15 years (%):	41 / 59
Life expectancy at birth (F/M, years) (2015):	66/ 62
GDP (PPP int \$):	2,370
Income status:	Lower middle
Number of 2 nd sub-national administrative level divisions, name:	187, Locality

EPIDEMIOLOGY

	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Endemic
Number of new cases (incidence):	2,829	3,503	43	0
Number of relapse ¹ cases:	73	122	N/A	0
Total number of cases:	2,902	3,625	43	0
Imported cases (#, %):	0, 0%	0, 0%	No data	No data
Gender distribution (% F) ^o :	35	No data	No data	N/A
Age group distribution (% , < 5/5-14/>14) ^o :	(10/60/30)	No data	(0/33/67)	N/A
Incidence rate (cases/10,000 population in endemic areas) ^o :	3.25	0.94	N/A	N/A
Number of endemic 2 nd sub-national administrative level divisions:	27	174	N/A	N/A
Population at risk ² (% , # at risk/total population) ^o :	25 % 8,696,636/40,235,000	93 % 37,419,625/40,235,000	N/A	N/A
Was there any outbreak?	No	No	N/A	N/A
Number of new ³ foci:	No data	0	N/A	N/A


N/A = Not applicable; ¹ Relapse in this country is defined as: "A patient with clinically and parasitologically confirmed VL within six months of successful treatment"; ² Defined as "Number of people living in 2nd sub-national administrative level endemic areas"; ³ Defined as "In this reporting period, an area at the 2nd sub-national administrative level reporting cases for the first time ever"; ^o Sociodemographic information has been provided for new cases; ^o Incidence and population at risk have been calculated with population census figure in 2008, adjusted by annual growth rate.

Monthly distribution of new cases (January-December)


2015	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	288	279	169	153	154	167	186	226	287	291	311	318
CL	244	254	190	356	375	411	467	211	177	209	233	376

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL= post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis

Visceral leishmaniasis




Cutaneous leishmaniasis




Incidence rate/10,000 (at the national level) and number of new cases from 1998 to 2015

Visceral leishmaniasis




Cutaneous leishmaniasis



Disease distribution of new VL and CL cases at locality level per 10,000 population (2015)

Visceral leishmaniasis




www.who.int/leishmaniasis/Map-VL-Sudan-2015.png

The boundaries and names shown and the designations used on these maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Map production: WHO/HTM/NTD/IDM

Cutaneous leishmaniasis



www.who.int/leishmaniasis/Map-CL-Sudan-2015.png

CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	2004
Type of surveillance:	Vertical
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	Bendiocarb/ Pyrethroid
Year latest national guidelines:	2014
Is leishmaniasis notifiable (mandatory report)?	Yes
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities:	36

DIAGNOSIS

	VL	CL	PKDL	MCL
Number of people screened actively for:	No data	No data	N/A	N/A
Number of people screened passively for:	9,916	No data	N/A	N/A
Cases diagnosed by RDT* (% , # RDT+/ total VL cases):	71% (2,001/2,829)	N/A	N/A	N/A
Proportion of positive RDT* (% , # RDT+/total RDT):	20% (2,001/9807)	N/A	N/A	N/A
Cases diagnosed by direct exam* (parasitology) (% , # slides + / total cases):	29% (812/2,829)	No data	N/A	N/A
Proportion of positive slides* (% , # slides + / total slides):	77% (812/1,055)	No data	N/A	N/A
Cases diagnosed clinically* (% , # clinical cases/ total cases):	0% (0/2,829)	No data	N/A	N/A
Proportion of CL cases with lesions equal to or greater than 4cm*:	N/A	No data	N/A	N/A
Proportion of CL cases with 4 or more lesions*(% , # CL cases/ total CL cases):	N/A	No data	N/A	N/A
Percentage of cases with HIV coinfection*:	0.2% (6/2,829)	N/A	0% (0/43)	N/A

N/A = Not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? **Yes**
- ▶ Antileishmanial medicines included in the National Medicine List: **Meglumine antimoniate, Sodium stibogluconate (SSG), Liposomal amphotericin B, Amphotericin B deoxycholate, Paramomycin, Pentamidine**

TREATMENT OUTCOME

	VL	CL
Proportion of cases treated*(% , # treated cases/ total cases):	100% (2,829/2,829)	78% (2,723/3,503)
Initial cure rate*(% , # cases initially cured /total cases):	68% (1,900/2,829)	26% (911/3,503)
Failure rate ⁴ *(% , # patients with treatment failure /total cases):	1% (23/2,829)	9% (309/3,503)
Case fatality rate*(% , # patients who died/ total cases):	2% (52/2,829)	0% (0/3,503)

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL= post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis

⁴ Failure in this country is defined as: "A patient who shows no\poor clinical response after 30 days of SSG treatment and presents with parasitology smear of grade 4+ or more"

* These indicators only apply to new cases